Overseas Expansion Through Distributor Networks, Overseas-Market Products and High-Value-Added Products
First written in FY2024. 1 of 3 entries say "Advanced", first in 2026-07-15. Latest entry: FY2026.
1 other company's latest entry also says "Raised".
- FY2026RaisedAnnual report
「While seeking to expand our share of the antigen testing product market, particularly in Asia, we will also expand our business in new markets such as Latin America through initiatives including the development of sales partners.」
In addition to the previous phased plan centered on an overseas distributor network, products adapted to overseas specifications and value-added products, the company explicitly identified new-market development including Latin America and Africa, as well as the overseas rollout of D-IA and SaMD, thereby broadening its scope. - 2026-07-15AdvancedManagement Planning
「Overseas sales of at least ¥2.5 billion in the fiscal year ending June 2031」
For overseas expansion, the company presented a quantitative overseas sales target, a target for WHO prequalification of D-IA tuberculosis POCT, and an expansion policy covering Asia, Latin America and the Caribbean, Africa and other regions. - FY2024First statedAnnual report
「In the short term, we are strengthening distributor networks in each region that handle our existing products. In the medium term, we will develop and roll out products tailored for overseas markets while undertaking a fundamental review of costs without compromising quality. In the long term, we will introduce newly developed, high-value-added products.」
The company sets out short-, medium-, and long-term time horizons, using distributor networks, overseas-specification products, and new product launches as successive measures.